Reply to: Comment on “Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review”-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reply to: Comment on “Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review”

Published:2017-12 Issue:6 Volume:77 Page:e169-e170
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

No Daniel J.,Amin Mina,Wu Jashin J.

Publisher

Elsevier BV

Subject

Dermatology

Reference6 articles.

1. Comment on “Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: a systematic review.”;Asahina;J Am Acad Dermatol,2017

2. Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: a systematic review;Gilbert;J Am Acad Dermatol,2015

3. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study;Asahina;J Dermatol,2010

4. Pharmaceuticals and Medical Devices Agency (PMDA) website. Available in Japanese at: http://www.pmda.go.jp/drugs/2010/P201000011/10015900_22000AMX01598_A100.pdf. Accessed on June 10, 2017.

5. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up;Menting;JAMA Dermatol,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP